A subcutaneous formulation of MSD's top-selling cancer immunotherapy, Keytruda, was non-inferior to the current intravenous version in a head-to-head trial, setting up regulatory filings.

After hours: March 13 at 7:55:57 PM EDT Loading Chart for FORM ...

Efficient data collection and user engagement are crucial for businesses and organizations. Artificial Intelligence (AI) has disrupted the form-building process, offering innovative solutions that ...